- Netflix: The Biggest Empty Promise Since Enron?
- Why Car Prices Vary From City To City
- Big Bank Phobia: Not Too Big to Fail
- Apple Should Still Fire Tim Cook
- Expect Your Health Care in Retirement to Hit $200,000

Oncothyreon: A Failed Drug Autopsy Performed By A Short Seller
Fund manager Martin Shkreli offers advice on how to avoid the next Oncothyreon blowup.
10:10AM 12/19/12

Nektar Therapeutics Is a Short
Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.
07:08AM 09/12/12